TURNOVER (x1000 DKK)
NET PROFIT (x1000 DKK)
Biotec Betaglucans AS
Closing information (x1000 DKK)
| Closing information | 2025/01 | 2024/01 | 2023/01 |
| Turnover |
29,075
|
21,219
|
11,127 |
| Financial expenses |
860
|
1,167
|
1,478 |
| Earnings before taxes |
4,893
|
2,244
|
1,621 |
| Total assets |
21,643
|
21,827
|
15,538 |
| Current assets |
12,410
|
16,592
|
13,500 |
| Current liabilities |
10,403
|
12,642
|
6,212 |
| Equity capital |
11,241
|
9,186
|
9,326 |
| - share capital |
636
|
657
|
687 |
Financial ratios
| Fiscal year | 2025/01 | 2024/01 | 2023/01 |
| Solvency |
51.9%
|
42.1%
|
60.0% |
| Turnover per employee | |||
| Profit as a percentage of turnover |
16.8%
|
10.6%
|
14.6% |
| Return on assets (ROA) |
26.6%
|
15.6%
|
19.9% |
| Current ratio |
119.3%
|
131.2%
|
217.3% |
| Return on equity (ROE) |
43.5%
|
24.4%
|
17.4% |
| Change turnover |
8,536
|
10,586
|
-6,674 |
| Change turnover % |
42%
|
100%
|
-37% |
| Chg. No. of employees | |||
| Chg. No. of employees % |
Total value of public sale
| Fiscal year | 2025/01 | 2024/01 | 2023/01 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.